Clinical Trial

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and tolerability of autologouschimeric antigen receptor T (CAR-T) cells targeting CD19/CD22/BCMA in patients with relapsed/refractory multiple myeloma.
Trial Details
NCT Number NCT06732232
Lead Sponsor Shanghai Cell Therapy Group Co.,Ltd
Conditions Relapsed, Refractory, Multiple Myeloma
Enrollment 12 participants
Start Date 2024-12-12
Primary Completion 2027-12-12 (estimated)
Study Completion 2027-12-12 (estimated)
Updated on ClinicalTrials.gov 2024-12-13